STOCK TITAN

Precision BioSciences (DTIL) director reports purchase of 2,700 shares

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Precision BioSciences director Stanley R. Frankel reported buying 2,700 shares of the company’s common stock on December 16, 2025 at a price of $4.70 per share. This insider purchase increased his directly held stake to 19,478 shares. The transaction was reported as a routine filing by a single reporting person.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Frankel Stanley

(Last) (First) (Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E. PETTIGREW ST., SUITE A-100

(Street)
DURHAM NC 27701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/16/2025 P 2,700 A $4.7 19,478 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Dario Scimeca, Attorney-in-Fact for Stanley R. Frankel 12/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Precision BioSciences (DTIL) disclose?

A company director, Stanley R. Frankel, disclosed the purchase of 2,700 shares of Precision BioSciences common stock.

On what date did the Precision BioSciences (DTIL) insider trade occur?

The reported transaction took place on December 16, 2025.

What price was paid per share in the latest Precision BioSciences (DTIL) insider purchase?

The director bought the common stock at a price of $4.70 per share.

How many Precision BioSciences (DTIL) shares does the director own after this transaction?

Following the reported trade, the director directly owns 19,478 shares of Precision BioSciences common stock.

What is the relationship of the reporting person to Precision BioSciences (DTIL)?

The reporting person, Stanley R. Frankel, is identified as a director of Precision BioSciences.

Was this Precision BioSciences (DTIL) insider filing submitted by multiple people?

No. The document shows it was filed by one reporting person, not a group.

Precision Biosciences

NASDAQ:DTIL

DTIL Rankings

DTIL Latest News

DTIL Latest SEC Filings

DTIL Stock Data

108.80M
21.40M
11.28%
44.24%
9.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DURHAM